- Simeprevir Sodium
-
- $0.00 / 1g
-
2025-09-11
- CAS:1241946-89-3
- Min. Order: 1g
- Purity: More Than 99%
- Supply Ability: 100kg/Month
- Simeprevir sodium
-
- $159.00 / 1mg
-
2025-08-21
- CAS:1241946-89-3
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Simeprevir sodium Basic information |
| | Simeprevir sodium Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:30.0(Max Conc. mg/mL);38.86(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.33(Max Conc. mg/mL);0.43(Max Conc. mM)
DMF:30.0(Max Conc. mg/mL);38.86(Max Conc. mM) | | form | A crystalline solid |
| | Simeprevir sodium Usage And Synthesis |
| Description | Simeprevir is an orally bioavailable and potent inhibitor of the hepatitis C virus (HCV) nonstructural protein 3/4A (NS3/4A) protease (Ki = 0.36 nM), a serine protease essential for HCV replication. It inhibits HCV viral replication with an EC50 value of 7.8 nM in Huh7 replicon cells using a luciferase-based assay. Simeprevir is effective against the HCV genotypes 1a and 1b in biochemical assays. In Huh7 replicon cells, it is synergistically effective when used in combination with IFN-α or NM-107 and has an additive effect when used with ribavirin . Formulations containing simeprevir have been used, alone or in combination with pegylated IFN-α and ribavirin, for the treatment of HCV. | | Uses | Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][4]. | | in vivo | Simeprevir (TMC435) has moderate terminal elimination half-life (t1/2=1.5 h and 4.1 h for rat (3 mg/kg, p.o.), monkey (3 mg/kg, p.o.))[3].
Simeprevir (TMC435350) exhibits a medium-slow rate of absorption, well distribution with the high concentration observed in the liver, and a low clearance[1].
Pharmacokinetic Parameters of Simeprevir (TMC435350) in male Sprague-Dawley rats[1].
| IV (2 mg/kg) | PO (10 mg/kg) | | CL (L/h/kg) | 0.505 | | | Vdss (h) | 0.49 | | | AUC0-24 (μM·h) | 5.21 | 2.79 | | Cmax (μM) | | 0.73 | | Tmax (h) | | 3.0 | | T1/2 (h) | | 2.8 | | F (%) | | 11 | | Liver/plasma ratio at 6 h | 63.5 | 32 |
| Animal Model: | Sprague-Dawley (SD) rats and cynomolgus monkeys[3] | | Dosage: | 3 mg/kg | | Administration: | PO; single dosage | | Result: | Time at which peak concentration (Tmax) of 1 hour and 2 hour for rat and monkey, respectively.
Concentration at 24 h after dosing (C24 h) of 0.9 and 2.3 ng/mL for rat and monkey, respectively.
AUC0-24h=1173 and 1409 ng·h/mL for rat and monkey, respectively. |
| | References | [1] Raboisson P, et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett. 2008 Sep 1;18(17):4853-8. DOI:10.1016/j.bmcl.2008.07.088
[2] Lin TI, et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor.Antimicrob Agents Chemother. 2009 Apr;53(4):1377-85. Epub 2009 Jan 26. DOI:10.1128/AAC.01058-08
[3] Rajagopalan R, et al. Preclinical Characterization and Human Microdose Pharmacokinetics of ITMN-8187, a Nonmacrocyclic Inhibitor of the Hepatitis C Virus NS3 Protease. Antimicrob Agents Chemother. 2016 Dec 27;61(1). pii: e01569-16. DOI:10.1128/AAC.01569-16
[4] Lo HS, et al. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir. ACS Cent Sci. 2021 May 26;7(5):792-802. DOI:10.1021/acscentsci.0c01186 |
| | Simeprevir sodium Preparation Products And Raw materials |
|